Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: heparin Clear all
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the GORE TIGRIS Vascular Stent

NCT01576055
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
TIGRIS Vascular Stent, BARD LifeStent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
34
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding "Heparin Resistance" in Cardiac Surgery

NCT01598883
View directory record Official record
Conditions
Cardiopulmonary Bypass, Altered Heparin Response
Interventions
Heparin, ATryn
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 23, 2026, 2:55 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Wet Heparinized Suction for Abdominal Cancer

NCT05041335
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions
wet heparinzed suction, Microsieve, No heparin flush, No microsieve
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
View directory record Official record
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO

NCT03318393
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Sep 23, 2026, 2:55 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947
View directory record Official record
Conditions
Frail Elderly, Coronary Artery Disease
Interventions
Off-pump coronary-artery bypass grafting, On-pump coronary-artery bypass grafting
Other
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
60 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 23, 2026, 2:55 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 23, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

NCT01461915
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Nab paclitaxel, Gemcitabine, Dociparstat
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 23, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional Results available

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Escondido, California • San Diego, California • Cartersville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 23, 2026, 2:55 AM EDT
Terminated Phase 1Phase 2 Interventional

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

NCT01621243
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
nab-paclitaxel, gemcitabine, placebo, Necuparanib
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 23, 2026, 2:55 AM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

NCT02706249
View directory record Official record
Conditions
Venous Thormboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
View directory record Official record
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 23, 2026, 2:55 AM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Early Phase 1 Interventional

Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

NCT01843634
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 23, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Phase 2 Interventional

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
REG1, Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 23, 2026, 2:55 AM EDT
Completed No phase listed Observational

Heparin Management During Cardiopulmonary Bypass in Children

NCT00146653
View directory record Official record
Conditions
Primary Condition: Heart Defects Requiring Surgery With CPB
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 6 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 23, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

NCT01161641
View directory record Official record
Conditions
Protein Losing Enteropathy
Interventions
ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 23, 2026, 2:55 AM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 23, 2026, 2:55 AM EDT
Completed Not applicable Interventional

Arterial Versus Venous Activated Clotting Time (ACT) Measurements During Atrial Fibrillation Ablations

NCT04285840
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Venous ACT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 23, 2026, 2:55 AM EDT